|
|
|
|
|
|
|
|
Managing Clinical Trials in Emerging Markets
|
|
|
|
Amgen's hub-and-spoke system combines control at home with the flexibility to respond to local needs
|
|
|
|
The San Diego Story
|
|
|
| By
William Looney
|
|
|
|
Building the commercial and policy base for effective collaboration in biotech
|
|
|
|
The Steep, Slow Climb
|
|
|
| By
Walter Armstrong
|
|
|
|
A surve of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade
|
|
|
|
|
|
|
|
|
The Night Stalkers: Keeping CEOs Awake in 2011
|
|
|
| By
William Looney
|
|
|
|
"Tops in Fraud" is a ruinous moniker for pharma—a business so dependent on basic issues of trust, integrity, quality and safety
|
|
|
|
The Night Stalkers
|
|
|
| By
William Looney
|
|
|
|
"Tops in Fraud" is a ruinous moniker for pharma—a business so dependent on basic issues of trust, integrity, quality and safety
|
|
|
|
|
|
|
|
|
Ensuring Drug Quality: A Complex Task in a Globalized Era
|
|
|
|
US Pharmacopeia has launched an ambitious moderniation campaign to ensure its standards keep pace with changes in the blobal marketplace
|
|
|
|
The List
|
|
|
| By
Walter Armstrong
|
|
|
|
It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome to 2011!
|
|
|
|
The Right Mix for 2011
|
|
|
| By
Eric Boothe
|
|
|
|
Incorporating the proper blend of media into your marketing initiatives will help to increase the flexibility and success of your campaigns
|
|
|
|
Politics & PDUFA
|
|
|
| By
Jill Wechsler
|
|
|
|
Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead
|
|
|
|
|
|